What is euvolemic hyponatremia?

Euvolemic Hyponatremia: Definition and Clinical Significance

Euvolemic hyponatremia is a state of low serum sodium (typically <135 mEq/L) occurring in patients with normal total body volume status—meaning no clinical evidence of volume depletion (no ascites, edema) or volume overload. 1

Key Defining Features

Euvolemic hyponatremia is characterized by:

• Serum sodium <135 mEq/L (though treatment thresholds vary by context)
• Normal extracellular fluid volume on physical examination
• Absence of ascites and edema (distinguishing it from hypervolemic hyponatremia) 2
• Absence of volume depletion signs (distinguishing it from hypovolemic hyponatremia)

Most Common Cause: SIADH

The syndrome of inappropriate antidiuresis (SIADH) is the most common etiology of euvolemic hyponatremia in both hospitalized patients and outpatients 3, 4. SIADH is diagnosed by:

• Decreased serum osmolality
• Inappropriately elevated urine osmolality (>100 mOsm/L)
• Elevated urine sodium levels
• Normal thyroid and adrenal function 3

Critical Differential Diagnoses

Before confirming SIADH, you must systematically exclude:

1. Thiazide diuretic use (common medication-induced cause)
2. Hypothyroidism (though the causal relationship remains debated 5)
3. Adrenal insufficiency (cortisol deficiency impairs free water excretion)
4. Cerebral salt wasting (clinical mimic of SIADH, particularly in neurosurgical patients)
5. Reset osmostat (another SIADH mimic) 3

Pathophysiology

The mechanism involves non-osmotic hypersecretion of vasopressin (ADH), which causes:

• Impaired free water excretion at the collecting duct
• Water retention without proportional sodium retention
• Dilutional hyponatremia despite normal total body volume 2

This differs fundamentally from hypervolemic hyponatremia (seen in cirrhosis, heart failure) where extracellular fluid expansion with ascites/edema is present, and from hypovolemic hyponatremia where true volume depletion exists.

Clinical Significance and Morbidity

Even mild chronic euvolemic hyponatremia (131-135 mEq/L) carries significant morbidity 6:

• Cognitive impairment and gait disturbances
• Increased fall risk (23.8% vs 16.4% in normonatremic controls, P<0.01)
• Higher fracture rates (23.3% vs 17.3% over 7.4 years, P<0.004)
• Secondary osteoporosis
• Increased hospital stay and mortality 6

Management Approach Based on Severity

For Asymptomatic Mild Hyponatremia (126-135 mEq/L):

• Adequate solute intake (salt and protein)
• Initial fluid restriction to 1,000 mL/day, adjusted based on response 1
• Monitor serum sodium levels

For Moderate Hyponatremia (120-125 mEq/L):

• Fluid restriction to 1,000 mL/day 1
• Consider oral urea (very effective and safe second-line therapy) 7
• Vaptans (vasopressin V2-receptor antagonists like tolvaptan) for refractory cases 2

For Severe Symptomatic Hyponatremia (<120 mEq/L with neurologic symptoms):

This is a medical emergency requiring immediate treatment 6:

• Hypertonic saline (3%) as 100-150 mL IV bolus
• Target: increase serum sodium by 4-6 mEq/L within 1-2 hours to reverse encephalopathy
• Maximum correction limit: 8-10 mEq/L per 24 hours to prevent osmotic demyelination syndrome (ODS) 1, 6
• Consider simultaneous desmopressin administration in high-risk patients to prevent overly rapid correction 3

Critical Pitfalls to Avoid

1. Never use 0.9% normal saline in SIADH: It acts as a hypotonic solution in these patients, causing rapid fluctuations in serum sodium—initially correcting too rapidly (risking ODS), then worsening hyponatremia post-infusion 3

2. Overcorrection causes osmotic demyelination syndrome: This devastating complication presents 2-7 days after rapid correction with dysarthria, dysphagia, quadriparesis, or death. Risk is highest in chronic hyponatremia, alcoholism, malnutrition, and advanced liver disease 1

3. Distinguish acute (<48 hours) from chronic (>48 hours) hyponatremia: Acute hyponatremia can be corrected rapidly without ODS risk; chronic hyponatremia requires gradual correction 1, 3

4. Fluid restriction alone often fails: Nearly half of SIADH patients don't respond to fluid restriction as first-line therapy, requiring second-line agents like urea or vaptans 7